TSL Express Daily News

STAMFORD, Conn.--(BUSINESS WIRE)--HealthCare Royalty (“HCRx” or the “Company”), a leading middle market royalty acquisition firm that has raised $7.6 billion in capital since inception, today announced several important firm developments:

Closing of Credit Facility for New Operating Business

HCRx is pleased to announce that the new permanent capital company, HCRx Holdings, L.P. (“HCRx Holdings”), it formed in 2022 held a final closing on a $680 million credit facility. The credit facility includes a $380 million term loan and a $300 million revolving credit facility; the revolving credit facility remains undrawn.

With the closing of this financing, the Company has over $1 billion of liquidity. HCRx Holdings will use its capital to expand its leading presence in the biopharmaceutical royalty acquisition space during a time of unprecedented market opportunity.

Closing of New Vehicle Focused on Debt Investments

HCRx is also pleased to announce that it has closed on a new vehicle that will be focused primarily on providing debt solutions to emerging biopharmaceutical companies.

“We appreciate the confidence shown by our bank group and investors in HCRx’s differentiated business model, strategic vision, and operational excellence,” said Clarke B. Futch, Founder, Chief Executive Officer and Chairman at HCRx. “It is an attractive time to be in the royalty financing market and HCRx is on track for a very productive year having already purchased royalties in a diverse set of products including Hemgenix, Relistor, Lumify, Rezurock, and Bexacat. We are also excited to have a source of capital focused on debt opportunities as that market looks much more attractive to us today than it has in years.”

Appointment of Josh House as West Coast Lead

HCRx has also appointed Josh C. House as an Executive Vice President based in San Francisco, CA.

“We are proud to welcome Josh to the HCRx team,” said Mr. Futch. “Josh brings a differentiated view to our investment process with 10 years of healthcare experience covering operational and investment banking roles. We look forward to leveraging both his knowledge and network as we continue support the funding needs of innovative biopharmaceutical companies on the West Coast.”

Prior to joining HCRx, Mr. House was chief financial officer of Hummingbird Bioscience, a clinical-stage antibody platform company focused on oncology and autoimmune diseases. Previously, Mr. House held business development roles at Consonance-HFW Acquisition Corp. and Atara Biotherapeutics, and was a vice president at Citigroup in the healthcare investment banking group where he covered west coast-based life sciences companies. During his career in the life sciences industry, he has executed equity, M&A and licensing transactions representing over $4 billion in transaction value. Mr. House holds a B.A. from Stanford University and J.D. and M.B.A. degrees from Columbia University.

About HealthCare Royalty

HCRx is a leading royalty acquisition company focused on commercial or near-commercial stage biopharmaceutical products. HCRx has raised $7.6 billion in capital since inception with offices in Stamford (CT), San Francisco, Boston and London. For more information, visit https://www.hcrx.com/. HEALTHCARE ROYALTY® and HCRx® are registered trademarks of HealthCare Royalty Management, LLC.

Contacts

Media:
Carlos Almodovar
(203) 487-8300
irinfo@hcrx.com